{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:32:32Z","timestamp":1792297952967,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Since its release, Dupilumab has shown great results in treating severe uncontrolled CRSwNP. However, there is a lack of real-world data beyond 12\u00a0months of follow-up, and it is not clear to what extent biomarkers are appropriate for monitoring and predicting the Dupilumab therapy success. Hence, this study aims to analyze biomarkers for monitoring therapy, predicting therapy success and assess the effect of Dupilumab in real-world settings.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The follow-up was performed with 104 patients retrospectively up to 22\u00a0months, assessing SNOT-22, NPS, olfactometry, ACS, FEV-1, and blood biomarkers (total serum IgE, Eosinophils, ECP). Patients were divided into subgroups depending on their pretherapeutic biomarker levels and subsequent development was analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There was substantially improvement in all clinical parameters up to 1\u00a0year and then continuously up to month 22. Patients with initially elevated baseline blood eosinophil counts (&gt;\u20090.5\u00a0billion\/L) had a trend of better SNOT-22 development after 1\u00a0year (\u2212\u200912.19 points, <jats:italic>p<\/jats:italic>\u2009=\u20090.03). The course of total serum IgE showed moderate correlation with almost all clinical variables obtained. Therapy was well tolerated with only mild and transient adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Dupilumab has considerably reduced symptoms and disease severity even beyond 1\u00a0year of treatment, supporting its role as targeted and effective treatment option for CRSwNP. Our data shows that total serum IgE is a promising biomarker for the monitoring during the treatment with Dupilumab. Elevated pre-therapeutic serum eosinophil counts may be a predictor of good subjective response to therapy. Larger cohorts and a long-term-follow-up over years are needed to further consolidate these findings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00405-024-08574-4","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T05:01:27Z","timestamp":1714971687000},"page":"4789-4805","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The value of biomarkers in the therapy of CRSwNP with biologicals\u2014a long-term follow-up of dupilumab therapy"],"prefix":"10.1007","volume":"281","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9326-9544","authenticated-orcid":false,"given":"Sven Ole","family":"Sarnoch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amra","family":"Pepi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Betz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Sophie","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"issue":"4","key":"8574_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaip.2016.04.012","volume":"4","author":"WW Stevens","year":"2016","unstructured":"Stevens WW, Schleimer RP, Kern RC (2016) Chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract 4(4):565\u2013572","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"Suppl S29","key":"8574_CR2","first-page":"1","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S et al (2020) European position paper on rhinosinusitis and nasal polyps 2020. Rhinology 58(Suppl S29):1\u2013464","journal-title":"Rhinology"},{"issue":"6","key":"8574_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2500\/ajra.2013.27.3981","volume":"27","author":"MR Chaaban","year":"2013","unstructured":"Chaaban MR, Walsh EM, Woodworth BA (2013) Epidemiology and differential diagnosis of nasal polyps. Am J Rhinol Allergy 27(6):473\u2013478","journal-title":"Am J Rhinol Allergy"},{"issue":"4","key":"8574_CR4","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s00405-022-07679-y","volume":"280","author":"F Jansen","year":"2023","unstructured":"Jansen F, Becker B, Eden JK, Breda PC, Hot A, Oqueka T et al (2023) Dupilumab (Dupixent((R))) tends to be an effective therapy for uncontrolled severe chronic rhinosinusitis with nasal polyps: real data of a single-centered, retrospective single-arm longitudinal study from a university hospital in Germany. Eur Arch Otorhinolaryngol 280(4):1741\u20131755","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"1","key":"8574_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4193\/Rhin17.255","volume":"57","author":"A Khan","year":"2019","unstructured":"Khan A, Vandeplas G, Huynh TMT, Joish VN, Mannent L, Tomassen P et al (2019) The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology 57(1):32\u201342","journal-title":"Rhinology"},{"issue":"4","key":"8574_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/194589240101500403","volume":"15","author":"M van Agthoven","year":"2001","unstructured":"van Agthoven M, Fokkens WJ, van de Merwe JP, Marijke van Bolhuis E, Uyl-de Groot CA, Busschbach JJ (2001) Quality of life of patients with refractory chronic rhinosinusitis: effects of filgrastim treatment. Am J Rhinol 15(4):231\u2013237","journal-title":"Am J Rhinol"},{"issue":"12","key":"8574_CR7","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/lary.21847","volume":"121","author":"ZM Soler","year":"2011","unstructured":"Soler ZM, Wittenberg E, Schlosser RJ, Mace JC, Smith TL (2011) Health state utility values in patients undergoing endoscopic sinus surgery. Laryngoscope 121(12):2672\u20132678","journal-title":"Laryngoscope"},{"issue":"1","key":"8574_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","volume":"147","author":"C Bachert","year":"2021","unstructured":"Bachert C, Han JK, Wagenmann M, Hosemann W, Lee SE, Backer V et al (2021) EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol 147(1):29\u201336","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"8574_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.iac.2018.06.006","volume":"38","author":"AD Workman","year":"2018","unstructured":"Workman AD, Kohanski MA, Cohen NA (2018) Biomarkers in chronic rhinosinusitis with nasal polyps. Immunol Allergy Clin North Am 38(4):679\u2013692","journal-title":"Immunol Allergy Clin North Am"},{"issue":"5","key":"8574_CR10","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc'h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S et al (2020) Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ralpha antibody, is required to broadly inhibit type 2 inflammation. Allergy 75(5):1188\u20131204","journal-title":"Allergy"},{"issue":"4","key":"8574_CR11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/all.13685","volume":"74","author":"K Jonstam","year":"2019","unstructured":"Jonstam K, Swanson BN, Mannent LP, Cardell LO, Tian N, Wang Y et al (2019) Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. Allergy 74(4):743\u2013752","journal-title":"Allergy"},{"issue":"4","key":"8574_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.iac.2004.06.008","volume":"24","author":"JW Steinke","year":"2004","unstructured":"Steinke JW (2004) Anti-interleukin-4 therapy. Immunol Allergy Clin N Am 24(4):599\u2013614, vi","journal-title":"Immunol Allergy Clin N Am"},{"issue":"6","key":"8574_CR13","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jaci.2007.03.048","volume":"119","author":"HF Rosenberg","year":"2007","unstructured":"Rosenberg HF, Phipps S, Foster PS (2007) Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol 119(6):1303\u20131310 (quiz 11\u20132)","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"8574_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40463-022-00570-0","volume":"51","author":"SJ Kilty","year":"2022","unstructured":"Kilty SJ, Lasso A (2022) Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps. J Otolaryngol Head Neck Surg 51(1):17","journal-title":"J Otolaryngol Head Neck Surg"},{"issue":"12","key":"8574_CR15","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/all.13875","volume":"74","author":"WJ Fokkens","year":"2019","unstructured":"Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J et al (2019) EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 74(12):2312\u20132319","journal-title":"Allergy"},{"issue":"3","key":"8574_CR16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/lary.26391","volume":"127","author":"AS DeConde","year":"2017","unstructured":"DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL (2017) Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope 127(3):550\u2013555","journal-title":"Laryngoscope"},{"key":"8574_CR17","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2147\/DDDT.S243053","volume":"14","author":"HH Kariyawasam","year":"2020","unstructured":"Kariyawasam HH, James LK, Gane SB (2020) Dupilumab: clinical efficacy of blocking IL-4\/IL-13 signalling in chronic rhinosinusitis with nasal polyps. Drug Des Dev Ther 14:1757\u20131769","journal-title":"Drug Des Dev Ther"},{"issue":"9","key":"8574_CR18","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/alr.22964","volume":"12","author":"C Bachert","year":"2022","unstructured":"Bachert C, Corren J, Lee SE, Zhang H, Harel S, Cunoosamy D et al (2022) Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS-24 and SINUS-52 trials. Int Forum Allergy Rhinol 12(9):1191\u20131195","journal-title":"Int Forum Allergy Rhinol"},{"issue":"10209","key":"8574_CR19","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394(10209):1638\u20131650","journal-title":"Lancet"},{"issue":"23","key":"8574_CR20","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL et al (2016) Real-world evidence\u2014what is it and what can it tell us? N Engl J Med 375(23):2293\u20132297","journal-title":"N Engl J Med"},{"key":"8574_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1744666X.2023.2207822","volume":"19","author":"B Yan","year":"2023","unstructured":"Yan B, Zhang L (2023) Biomarkers guiding biological therapeutic strategies in chronic rhinosinusitis with nasal polyps: an emerging challenge. Expert Rev Clin Immunol 19:1\u20134","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"8574_CR22","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/all.14906","volume":"77","author":"S Fujieda","year":"2022","unstructured":"Fujieda S, Matsune S, Takeno S, Ohta N, Asako M, Bachert C et al (2022) Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status. Allergy 77(1):186\u2013196","journal-title":"Allergy"},{"key":"8574_CR23","unstructured":"Team RC. R: a language and environment for statistical computing. 4.2.2 ed. 2023."},{"issue":"1","key":"8574_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12948-022-00171-2","volume":"20","author":"E Nettis","year":"2022","unstructured":"Nettis E, Brussino L, Patella V, Bonzano L, Detoraki A, Di Leo E et al (2022) Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life. Clin Mol Allergy 20(1):6","journal-title":"Clin Mol Allergy"},{"issue":"3","key":"8574_CR25","first-page":"203","volume":"61","author":"R Boscke","year":"2023","unstructured":"Boscke R, Heidemann M, Bruchhage KL (2023) Dupilumab for chronic rhinosinusitis with nasal polyps: real-life retrospective 12-month effectiveness data. Rhinology 61(3):203\u2013213","journal-title":"Rhinology"},{"key":"8574_CR26","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.295","volume":"102","author":"S Miyamoto","year":"2022","unstructured":"Miyamoto S, Imai Y, Natsuaki M, Yamanishi K, Kanazawa N (2022) Long-term remission of atopic dermatitis after discontinuation of dupilumab. Acta Derm Venereol 102:adv00731","journal-title":"Acta Derm Venereol"},{"issue":"26","key":"8574_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhino16.248","volume":"54","author":"T Hummel","year":"2017","unstructured":"Hummel T, Whitcroft KL, Andrews P, Altundag A, Cinghi C, Costanzo RM et al (2017) Position paper on olfactory dysfunction. Rhinol Suppl 54(26):1\u201330","journal-title":"Rhinol Suppl"},{"issue":"3","key":"8574_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/chemse\/bjt072","volume":"39","author":"I Croy","year":"2014","unstructured":"Croy I, Nordin S, Hummel T (2014) Olfactory disorders and quality of life\u2014an updated review. Chem Senses 39(3):185\u2013194","journal-title":"Chem Senses"},{"issue":"5","key":"8574_CR29","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.anai.2021.01.012","volume":"126","author":"TM Laidlaw","year":"2021","unstructured":"Laidlaw TM, Bachert C, Amin N, Desrosiers M, Hellings PW, Mullol J et al (2021) Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma. Ann Allergy Asthma Immunol 126(5):584-592.e1","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"8574_CR30","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1111\/coa.13177","volume":"43","author":"KM Phillips","year":"2018","unstructured":"Phillips KM, Hoehle LP, Caradonna DS, Gray ST, Sedaghat AR (2018) Minimal clinically important difference for the 22-item sinonasal outcome test in medically managed patients with chronic rhinosinusitis. Clin Otolaryngol 43(5):1328\u20131334","journal-title":"Clin Otolaryngol"},{"key":"8574_CR31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2147\/TCRM.S192392","volume":"16","author":"GD Brooks","year":"2020","unstructured":"Brooks GD (2020) Updated evaluation of dupilumab in the treatment of asthma: patient selection and reported outcomes. Ther Clin Risk Manag 16:181\u2013187","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"8574_CR32","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","volume":"149","author":"C Bachert","year":"2022","unstructured":"Bachert C, Sousa AR, Han JK, Schlosser RJ, Sowerby LJ, Hopkins C et al (2022) Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count. J Allergy Clin Immunol 149(5):1711-1721.e6","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"8574_CR33","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","volume":"149","author":"C Bachert","year":"2022","unstructured":"Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C et al (2022) Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol 149(4):1309-1317.e12","journal-title":"J Allergy Clin Immunol"},{"issue":"45","key":"8574_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000031031","volume":"101","author":"M Bertlich","year":"2022","unstructured":"Bertlich M, Freytag S, Dombrowski T, Jurmeister P, Spiegel JL, Bertlich I et al (2022) Subgroups in the treatment of nasal polyposis with dupilumab: a retrospective study. Medicine 101(45):e31031","journal-title":"Medicine"},{"issue":"10","key":"8574_CR35","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1111\/all.15844","volume":"78","author":"FS Ryser","year":"2023","unstructured":"Ryser FS, Yalamanoglu A, Valaperti A, Br\u00fchlmann C, Mauthe T, Traidl S et al (2023) Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis. Allergy 78(10):2712\u20132723","journal-title":"Allergy"},{"key":"8574_CR36","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.2147\/DDDT.S226575","volume":"14","author":"HH Kariyawasam","year":"2020","unstructured":"Kariyawasam HH, James LK (2020) Chronic rhinosinusitis with nasal polyps: targeting IgE with anti-IgE omalizumab therapy. Drug Des Dev Ther 14:5483\u20135494","journal-title":"Drug Des Dev Ther"},{"issue":"26","key":"8574_CR37","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"KF Rabe","year":"2018","unstructured":"Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L et al (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 378(26):2475\u20132485","journal-title":"N Engl J Med"},{"issue":"5","key":"8574_CR38","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","volume":"35","author":"WW Busse","year":"2018","unstructured":"Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB et al (2018) Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy\/safety in patients with uncontrolled, moderate-to-severe asthma. Adv Ther 35(5):737\u2013748","journal-title":"Adv Ther"},{"issue":"11","key":"8574_CR39","doi-asserted-by":"publisher","first-page":"5231","DOI":"10.1007\/s00405-022-07389-5","volume":"279","author":"A Vinciguerra","year":"2022","unstructured":"Vinciguerra A, Rampi A, Yacoub MR, Tresoldi M, Tanzini U, Bussi M et al (2022) Hypereosinophilia management in patients with type 2 chronic rhinosinusitis treated with dupilumab: preliminary results. Eur Arch Otorhinolaryngol 279(11):5231\u20135238","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"11","key":"8574_CR40","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1055\/a-1908-3074","volume":"101","author":"L Klimek","year":"2022","unstructured":"Klimek L, F\u00f6rster-Ruhrmann U, Olze H, Beule AG, Chaker AM, Hagemann J et al (2022) Empfehlungen zur \u00dcberpr\u00fcfung der Wirksamkeit und Verlaufsdokumentation von Dupilumab bei chronischer\u00a0Rhinosinusitis mit Nasenpolypen (CRSwNP) im deutschen Gesundheitssystem. Laryngorhinootologie 101(11):855\u2013865. https:\/\/www.thieme-connect.com\/products\/ejournals\/abstract\/10.1055\/a-1908-3074","journal-title":"Laryngorhinootologie"},{"issue":"4","key":"8574_CR41","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1398-9995.2007.01327.x","volume":"62","author":"MC Munthe-Kaas","year":"2007","unstructured":"Munthe-Kaas MC, Gerritsen J, Carlsen KH, Undlien D, Egeland T, Skinningsrud B et al (2007) Eosinophil cationic protein (ECP) polymorphisms and association with asthma, s-ECP levels and related phenotypes. Allergy 62(4):429\u2013436","journal-title":"Allergy"},{"issue":"1","key":"8574_CR42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1465-9921-12-10","volume":"12","author":"J Bystrom","year":"2011","unstructured":"Bystrom J, Amin K, Bishop-Bailey D (2011) Analysing the eosinophil cationic protein\u2014a clue to the function of the eosinophil granulocyte. Respir Res 12(1):10","journal-title":"Respir Res"},{"issue":"4","key":"8574_CR43","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/alr.22664","volume":"11","author":"PC Lu","year":"2021","unstructured":"Lu PC, Lee TJ, Huang CC, Chang PH, Chen YW, Fu CH (2021) Serum eosinophil cationic protein: a prognostic factor for early postoperative recurrence of nasal polyps. Int Forum Allergy Rhinol 11(4):766\u2013772","journal-title":"Int Forum Allergy Rhinol"},{"issue":"10","key":"8574_CR44","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","volume":"10","author":"ME Wechsler","year":"2022","unstructured":"Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A et al (2022) Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. J Allergy Clin Immunol Pract 10(10):2695\u20132709","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"8574_CR45","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1002\/alr.23212","volume":"13","author":"A Rampi","year":"2023","unstructured":"Rampi A, Tanzini U, Vinciguerra A, Dan\u00e8 G, Moroni L, Yacoub MR et al (2023) Early increase in eosinophil count may predict long-term hypereosinophilia during dupilumab treatment: a 2-year observational study. Int Forum Allergy Rhinol 13(12):2244\u20132247","journal-title":"Int Forum Allergy Rhinol"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-024-08574-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-024-08574-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-024-08574-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T22:03:19Z","timestamp":1726178599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-024-08574-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["8574"],"URL":"https:\/\/doi.org\/10.1007\/s00405-024-08574-4","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"assertion":[{"value":"25 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ASH received honoraria for lectures and travel expenses from Sanofi, GSK and Novartis and participated in advisory boards. There are no conflicts of interest for any of the other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the ethics committee of Hamburg, Germany (2020-10264-BO-ff).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}